{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:40:11Z","timestamp":1748972411474,"version":"3.41.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Standard and proper antituberculosis (anti-TB) treatment is essential for patients with TB, and rifamycin antibiotics are key components of anti-TB therapy. Therapeutic drug monitoring (TDM) of rifamycin antibiotics can shorten the time to response and complete treatment of TB. Notably, antimicrobial activities of the major active metabolites of rifamycin are similar to those of their parent compounds. Thus, a rapid and simple assay was developed for simultaneous determination of rifamycin antibiotics and their major active metabolites in plasma to evaluate their impact on target peak concentrations. Here, the authors have developed and validated a method for simultaneous determination of rifamycin antibiotics and their active metabolites in human plasma using ultrahigh-performance liquid chromatography tandem mass spectrometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Analytical validation of the assay was performed in accordance with the bioanalytical method validation guidance for industry described by the US Food and Drug Administration and the guidelines for bioanalytical method validation described by the European Medicines Agency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The drug concentration quantification method for rifamycin antibiotics, including rifampicin, rifabutin, and rifapentine, and their major active metabolites was validated. Significant differences in the proportions of active metabolites in rifamycin antibiotics may affect the redefinition of their effective concentration ranges in the plasma. The method developed herein is expected to redefine the ranges of \u201ctrue\u201d effective concentrations of rifamycin antibiotics (including parent compounds and their active metabolites).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The validated method can be successfully applied for high-throughput analysis of rifamycin antibiotics and their active metabolites for TDM in patients receiving anti-TB treatment regimens containing these antibiotics. Proportions of active metabolites in rifamycin antibiotics markedly varied among individuals. Depending on the clinical indications of patients, the therapeutic ranges for rifamycin antibiotics may be redefined.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001098","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T16:44:30Z","timestamp":1681922670000},"page":"566-570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous Determination of Rifamycin Antibiotics and Their Active Metabolites in Human Plasma Using UHPLC-MS\/MS to Evaluate Their Impact on Target Peak Concentrations: A Short Communication"],"prefix":"10.1097","volume":"45","author":[{"given":"Ling-jie","family":"Wu","sequence":"first","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"},{"name":"Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-jie","family":"Ye","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-long","family":"Zhang","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"},{"name":"Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-xian","family":"Zheng","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"},{"name":"Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-long","family":"Liu","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"},{"name":"Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1038\/s41598-020-69228-z","article-title":"Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics","volume":"10","author":"Dyavar","year":"2020","journal-title":"Sci Rep."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"113076","DOI":"10.1016\/j.jpba.2019.113076","article-title":"Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS\/MS","volume":"180","author":"Wu","year":"2020","journal-title":"J Pharm Biomed Anal."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2018.10.027","article-title":"Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry","volume":"1105","author":"Sundell","year":"2019","journal-title":"J Chromatogr B."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography- electrospray ionization-tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003088-199528020-00003","article-title":"Clinical pharmacokinetics of rifabutin","volume":"28","author":"Skinner","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000502","article-title":"Dried blood spot analysis for therapeutic drug monitoring of antipsychotics: drawbacks of its clinical application","volume":"40","author":"Kloosterboer","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1128\/AAC.01730-13","article-title":"Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis","volume":"58","author":"Egelund","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.023","article-title":"Troubleshooting carry-over of LC-MS\/MS method for rifampicin, clarithromycin and metabolites in human plasma","volume":"917-918","author":"Vu","year":"2013","journal-title":"J Chromatogr B."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","article-title":"Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS\/MS","volume":"121","author":"Vu","year":"2014","journal-title":"Talanta"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jchromb.2009.04.038","article-title":"Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry","volume":"877","author":"de Velde","year":"2009","journal-title":"J Chromatogr B."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"112775","DOI":"10.1016\/j.jpba.2019.07.023","article-title":"Development and validation of an LC-MS\/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma","volume":"176","author":"Gray","year":"2019","journal-title":"J Pharm Biomed Anal."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2014.11.011","article-title":"Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS","volume":"104","author":"Winchester","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"114774","DOI":"10.1016\/j.jpba.2022.114774","article-title":"Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk","volume":"215","author":"Mkhize","year":"2022","journal-title":"J Pharm Biomed Anal."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/infdis\/125.5.486","article-title":"Killing of intraleukocytie staphylococcus aureus by rifampin: in-vitro and in-vivo studies","volume":"125","author":"Mandell","year":"1972","journal-title":"J Infect Dis."},{"issue":"Suppl 1","key":"R20-20250603","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1345\/aph.18450","article-title":"Rifapentine: its role in the treatment of tuberculosis","volume":"33","author":"Temple","year":"1999","journal-title":"Ann Pharmacother."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:13:11Z","timestamp":1748970791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001098","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"2022-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}